ENDRA Life Sciences Inc. (NASDAQ:NDRAU) Files An 8-K Regulation FD DisclosureItem 7.01 Regulation FD Disclosure.
ENDRA Life Sciences Inc. (NASDAQ:NDRAU) Files An 8-K Regulation FD Disclosure
On June 1, 2017, ENDRA Life Sciences Inc. (the “Company”) posted presentation materials (the “Investor Presentation”) to the investor relations section of the Company’s website at http://www.endrainc.com. The investor relations section of the Company’s website contains additional information that may be of interest to investors. The Investor Presentation is also furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
9.01. Financial Statements and Exhibits.
The exhibits required to be filed as a part of this Current Report on Form 8-K are listed in the Exhibit Index attached hereto and incorporated herein by reference.
About ENDRA Life Sciences Inc. (NASDAQ:NDRAU)
ENDRA Life Sciences Inc. is engaged in commercialization of an enhanced ultrasound technology for the pre-clinical research market. The Company’s Nexus 128 system combines light-based thermoacoustics and ultrasound, to address the imaging needs of researchers studying disease models in pre-clinical applications. The Company is involved in developing TAEUS for incorporation into new ultrasound systems. The TAEUS platform has capabilities and potential clinical applications, such as enabling ultrasound to distinguish fat from lean tissue; enabling traditional ultrasound to visualize changes in tissue temperature, in real time; enabling ultrasound to view blood vessels from any angle, using only a saline solution contrasting agent, unlike Doppler ultrasound which requires precise viewing angles, and enabling ultrasound to image blood flow at the capillary level in a region, organ or tissue. ENDRA Life Sciences Inc. (NASDAQ:NDRAU) Recent Trading Information
ENDRA Life Sciences Inc. (NASDAQ:NDRAU) closed its last trading session down -0.14 at 5.06 with 1,020 shares trading hands.
ENDRA Life Sciences Inc. is engaged in commercialization of an enhanced ultrasound technology for the pre-clinical research market. The Company’s Nexus 128 system combines light-based thermoacoustics and ultrasound, to address the imaging needs of researchers studying disease models in pre-clinical applications. The Company is involved in developing TAEUS for incorporation into new ultrasound systems. The TAEUS platform has capabilities and potential clinical applications, such as enabling ultrasound to distinguish fat from lean tissue; enabling traditional ultrasound to visualize changes in tissue temperature, in real time; enabling ultrasound to view blood vessels from any angle, using only a saline solution contrasting agent, unlike Doppler ultrasound which requires precise viewing angles, and enabling ultrasound to image blood flow at the capillary level in a region, organ or tissue. ENDRA Life Sciences Inc. (NASDAQ:NDRAU) Recent Trading Information
ENDRA Life Sciences Inc. (NASDAQ:NDRAU) closed its last trading session down -0.14 at 5.06 with 1,020 shares trading hands.
